John Kapeghian has joined CiToxLAB, a CRO in the field of non-clinical research, as Senior Director of Toxicology in North America (Montreal, Canada). He has 30 years of experience in preclinical drug safety.
Kapeghian is a renowned regulatory toxicologist with skills in study design and implementation, data evaluation and report review, FDA pre-IND meeting representation and briefing document preparation, as well as Investigator Brochure and IND/NDA/BLA preparation.
He was formerly head of Experimental Toxicology at Ciba Pharmaceuticals (now Novartis) and then joined Charles River Laboratories where he established and led the Navigator Scientific and Regulatory Consulting Group and Programme Management Team. As President of Preclinical Safety Associates, he has recently collaborated with pharmaceutical and biotechnology companies worldwide to advise on programmes, study design and to monitor non-clinical regulatory packages.
Dr Jean-Francois Le Bigot, Chairman and CEO of the CiToxLAB Group, said: 'CiToxLAB will celebrate its 45th anniversary in 2014, just three years after CIT merged with LAB-Research. CiToxLAB continuously invests in new techniques to validate in vivo and in vitro models. New safety pharmacology models have been recently implemented in NHPs and minipigs. We also invested in new methods for biomarkers in genomics, flow cytometry and immunohistochemistry. The hiring of John Kapeghian will make our Montreal site even more attractive for our clients in North America and reflects our mission to make CiToxLAB a science-driven CRO that offers the best scientific expertise to customers.'
